BPC-157 and TB-500 are the two peptides people mention most for injuries, often together as the "Wolverine" stack. Online, the benefits sound settled: faster tendon healing, less joint pain, a calmer gut. The research is more lopsided than that. There is a large pile of animal work and almost no controlled human data. Here is what each peptide is, what the studies actually show and what is still unknown.
What they are
- BPC-157 is a synthetic 15-amino-acid peptide based on a fragment of a protein found in human stomach juice. Most of the research comes from one group at the University of Zagreb in Croatia. See our BPC-157 brief.
- TB-500 is the name used for synthetic material based on thymosin beta-4, a 43-amino-acid protein found in almost every cell, where it holds actin, the building block of the cell's internal skeleton. Many TB-500 products are a short seven-amino-acid fragment of it rather than the full protein. See our TB-500 brief.
How they are thought to work
In animal and cell studies the two peptides seem to act on different parts of healing, which is the logic behind combining them:
- BPC-157 is linked to new blood-vessel growth, nitric oxide signaling and protection of the gut lining. In tendon cells it sped up how quickly cells spread and migrated without making them multiply faster (Chang et al., 2011). Its exact receptor is unknown.
- Thymosin beta-4 controls how fast cells can rebuild their skeleton, which affects how quickly they move into a wound. Studies link it to new blood vessels, less inflammation and less scarring.
What the animal research shows
For BPC-157, hundreds of rodent studies report faster healing of tendon, ligament, muscle, bone and gut injuries. A classic example: rats with a cut Achilles tendon healed faster and more strongly with BPC-157 (Staresinić et al., 2003). For thymosin beta-4, animal studies report faster healing of skin wounds, the cornea and heart tissue after injury.
These signals are consistent, but two cautions apply. Most BPC-157 studies come from a single research group, so independent replication is limited. And animal healing results often fail to carry over to people.
What the human research shows
BPC-157: a few small studies, none controlled
- Knee pain (2021): a review of patient charts at one clinic, with phone follow-up. Of 16 people who received knee injections, 12 got BPC-157 alone and 4 got BPC-157 plus thymosin beta-4. Fourteen of the 16 (87.5%) said their pain improved. There was no comparison group and no objective measurement, so a placebo effect cannot be ruled out.
- Interstitial cystitis (2024): 12 women with this painful bladder condition received a single BPC-157 injection into the bladder wall. Ten reported their symptoms resolved, and no side effects were reported. Again, there was no control group.
- An early drug program: in the early 2000s, a company tested BPC-157 under the code PL 14736 for ulcerative colitis. A phase 1 study in healthy men found it well tolerated, but no efficacy results from patients were ever published, and development stopped.
A 2025 systematic review of BPC-157 in sports medicine screened 544 records and found 36 relevant studies. Thirty-five were in animals or cells; one was in people (the knee study above). The authors concluded that human safety "remains unknown."
Thymosin beta-4: real trials, mixed results
Full-length thymosin beta-4 has been tested in people as a drug, mostly by the company RegeneRx and its partners:
- Intravenous form: a phase 1 study in 40 healthy volunteers found no dose-limiting toxicity or serious side effects.
- Wound gel: in a phase 2 trial in 73 people with leg ulcers, 33% healed by day 84 on the middle dose versus 24% on placebo. The study was designed mainly to test safety, not to prove benefit.
- Eye drops: three phase 3 dry-eye trials with more than 1,600 people missed their main goals, though one showed less eye grittiness. Trials for a nerve-related corneal condition also missed their main goals, partly because of high placebo responses. Results from another phase 3 trial were expected in late 2026.
No thymosin beta-4 product is FDA-approved, and none of these trials tested the short TB-500 fragment sold online. At the FDA's July 2026 advisory meeting, reviewers noted that no studies had been conducted on TB-500 itself.
The combination
There are no controlled trials of BPC-157 and TB-500 together. The only human data are the four patients in the 2021 knee study. The idea that the pair works better than either alone comes from animal mechanisms, not from testing.
Safety questions
- Theoretical cancer concern: both peptides promote new blood-vessel growth and cell migration, which help healing but are also processes tumors use. FDA reviewers raised this as a theoretical concern for BPC-157 and TB-500 in 2026. It has not been shown in people, but long-term and cancer studies have not been done either.
- Other signals: the FDA also said repeat-dose animal studies of BPC-157 showed possible effects on blood clotting and liver function, and that BPC-157 is "not well-characterized" chemically.
- Product quality: a 2026 analysis of about 6,300 test reports on research-grade peptides found that 10% of TB-500 samples and 3.5% of BPC-157 samples did not contain the stated compound. That study is a preprint and has not been peer reviewed. Always match a vial's lot to its certificate of analysis.
- Sport: both are banned by the World Anti-Doping Agency. BPC-157 is listed under non-approved substances, and thymosin beta-4 and its derivatives, including TB-500, are listed under peptide hormones and growth factors.
Regulatory status
- Neither is FDA-approved for any use. Both are sold as research compounds.
- Compounding: in July 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend each of BPC-157 and TB-500 for the list of bulk substances pharmacies may compound. FDA staff had recommended against them. The vote was advisory. Read what the July 2026 vote actually means.
- October 2026 policy: on October 28, 2026, HHS announced that while rulemaking continues, it will not take action against state-licensed (503A) pharmacies that compound BPC-157, TB-500 and four other peptides for individual patients with a prescription, under strict conditions. One condition is that each product contain a single active ingredient, so a combined BPC-157 and TB-500 product does not qualify. The policy is not an approval, and it excludes products sold as research chemicals.
The bottom line
BPC-157 and TB-500 have a strong animal story and a plausible biological rationale. What they do not have is a controlled human trial showing that either one, or the two together, speeds healing or relieves pain in people. The benefits you read about online run well ahead of the evidence.
For the blend itself, see our BPC-157 + TB-500 brief.
Key references
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Alternative Therapies in Health and Medicine. 2024.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. 2025;21(4):485-495.
- Staresinić M, Sebecić B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth00110-4). Journal of Orthopaedic Research. 2003;21(6):976-983.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:223-229.
- BioSpace. RegeneRx reassesses pipeline in light of development delays with lead asset, August 2022.
- Ophthalmology Times. HLB Therapeutics misses primary endpoint in phase 3 SEER-3 trial of RGN-259, 2025.
- Bass, Berry & Sims. FDA advisory committee recommends six peptides for compounding, 2026.
- McDermott Will & Schulte. Bulk list bound? PCAC backs majority of peptides in two-day public meeting, July 2026.
- Baker Hostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, October 2026.
- U.S. Department of Health and Human Services. HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, October 2026.
- Mendias CL, Awan TM. Evaluation of research grade peptides marketed directly to consumers reveals extensive variability in purity and measured abundance. Preprints.org, April 2026 (not peer reviewed).
- World Anti-Doping Agency. 2026 Prohibited List (sections S0 and S2).
This post is educational. It does not give dosing guidance or recommend using any compound in people or animals.